Abstract:Hongmei Yang, 1, &ast Zhongqi Liu, 1, &ast Fan Liu, 1, 2, &ast Haixuan Wu, 1 Xiaoyan Huang, 1 Rong Huang, 1 Phei Er Saw, 3, 4 Minghui Cao 1, 2 1 Department of Anesthesiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 2 Department of Anesthesiology, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516600, People's Republic of China; 3 Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China; 4 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, People's Republic of China &astThese authors contributed equally to this work Correspondence: Phei Er Saw; Minghui Cao, Email ; Background: Opioids are irreplaceable analgesics owing to the lack of alternative analgesics that offer opioid-like pain relief. However, opioids have many undesirable central side effects. Restricting opioids to peripheral opioid receptors could reduce those effects while maintaining analgesia. Methods: To achieve this goal, we developed Tet1-LNP (morphine), a neural-targeting lipid nanoparticle encapsulating morphine that could specifically activate the peripheral opioid receptor in the dorsal root ganglion (DRG) and significantly reduce the side effects caused by the activation of opioid receptors in the brain. Tet1-LNP (morphine) were successfully prepared using the thin-film hydration method. In vitro, Tet1-LNP (morphine) uptake was assessed in differentiated neuron-like PC-12 cells and dorsal root ganglion (DRG) primary cells. The uptake of Tet1-LNP (morphine) in the DRGs and the brain was assessed in vivo. Von Frey filament and Hargreaves tests were used to assess the antinociception of Tet1-LNP (morphine) in the chronic constriction injury (CCI) neuropathic pain model. Morphine concentration in blood and brain were evaluated using ELISA. Results: Tet1-LNP (morphine) had an average size of 131 nm. Tet1-LNP (morphine) showed high cellular uptake and targeted DRG in vitro. CCI mice treated with Tet1-LNP (morphine) experienced prolonged analgesia for nearly 32 h compared with 3 h with free morphine ( p < 0.0001). Notably, the brain morphine concentration in the Tet1-LNP (morphine) group was eight-fold lower than that in the morphine group ( p < 0.0001). Conclusion: Our study presents a targeted lipid nanoparticle system for peripheral neural delivery of morphine. We anticipate Tet1-LNP (morphine) will offer a safe formulation for chronic neuropathic pain treatment, and promise further development for clinical applications. Keywords: lipid nanoparticle, Tet1, peripheral nerve-targeted, pain management, chronic neuropathic pain Opioids remain the mainstay of analgesic treatment for perioperative, severe, acute, and chronic pain. However, opioid clinical effectiveness is restricted due to adverse side effects that are mainly caused by activating the μ-opioid receptors in the central nervous system (CNS), 1 including sedation, apnea, tolerance, and addiction which lead to an epidemic of overdoses, death, and abuse. 2 Therefore, there is an urgent need to develop novel therapeutic strategies for the management of pain. Currently, various approaches are being explored, including focusing on μ-opioid receptor (MOR) splice variants, generating biased agonists, or targeting other receptors such as heteromers with MOR. 3 Despite significant advances, clinical translation of these strategies remains challenging. Researchers have reduced opioid side effects by regulating transient receptor potential vanilloid 1 (TRPV1) receptors. 4 However, TRPV1 antagonists may increase the thermal pain threshold in humans, potentially increasing the risk of burn injury. 5 As central effects account for the majority of opioid-related adverse effects, the use of opioid receptors only in peripheral sensory neurons is a promising therapeutic strategy to limit central adverse effects while maintaining analgesic effects. 3 There is growing evidence that peripheral sensory neurons mediate antinociceptive effects. 6,7 Primary sensory neurons, with cell bodies within dorsal root ganglia (DRGs), project fibers to the peripheral terminals of sensory neurons 8 and opioid receptors exist in DRG neurons of different diameters and prototypical sensory neuropeptides. 9 When there is a pain signal, opioid recep -Abstract Truncated-

Tens Stimulates Constitutive Nitric Oxide Release Via Opiate Signaling in Invertebrate Neural Tissues

Increased Methylation of the MOR Gene Proximal Promoter in Primary Sensory Neurons Plays a Crucial Role in the Decreased Analgesic Effect of Opioids in Neuropathic Pain

Morphine-responsive neurons that regulate mechanical antinociception

Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine Via Peripheral Opioid Receptors

Sensitization of human and rat nociceptors by low dose morphine is toll-like receptor 4-dependent

Neurobiological mechanisms of TENS-induced analgesia

Research Progress in Interactions Between Nitric Oxide, Nitric Oxide Synthase and Morphine Tolerance

Brain opioid-receptors are involved in mediating peripheral electric stimulation-induced inhibition of morphine conditioned place preference in rats

Inhibition of MPEP on the Development of Morphine Antinociceptive Tolerance and the Biosynthesis of Neuronal Nitric Oxide Synthase in Rat Spinal Cord.

Role of Opioid Receptors (μ, Δ 1 , Δ 2 ) in Modulating Responses of Nociceptive Neurons in the Superficial and Deeper Dorsal Horn of the Medulla (trigeminal Nucleus Caudalis) in the Rat

Transcutaneous Electrical Nerve Stimulation in Rodent Models of Neuropathic Pain: A Meta-Analysis

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury

Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats.

Activation of µ-δ opioid receptor heteromers inhibits neuropathic pain behavior in rodents.

A54 DELTA OPIOID RECEPTOR SIGNALING MEDIATES OPIOID INDUCED TOLERANCE AND HYPERALGESIA IN COLONIC SENSORY NERVES

TET1-Lipid Nanoparticle Encapsulating Morphine for Specific Targeting of Peripheral Nerve for Pain Alleviation

Effect of Electro-Acupuncture at ST36 and SP6 on the cAMP -CREB Pathway and mRNA Expression Profile in the Brainstem of Morphine Tolerant Mice

Blockade of Peripheral Nociceptive Signal Input Relieves the Formation of Spinal Central Sensitization and Retains Morphine Efficacy in a Neuropathic Pain Rat Model.

Oxytocin in the Periaqueductal Gray Participates in Pain Modulation in the Rat by Influencing Endogenous Opiate Peptides

Mitogen‐activated protein kinase signaling mediates opioid‐induced presynaptic <scp>NMDA</scp> receptor activation and analgesic tolerance